$MO

Altria Group (MO), a tobacco company, has seen total returns of over 24% in 2026, outperforming the S&P 500. The company reported Q2 2026 revenue of $5.35 billion and earnings of $1.37 per share, down 2.8% year-over-year. Despite concerns about declining cigarette usage, Altria has raised its dividend by 4.7% and announced a contract with Philip Morris International. The stock trades at 12 times forward earnings with a 6.4% forward dividend yield.

Altria (MO) raised its quarterly dividend to $1.11, yielding 6.4% forward. Fiscal 2025 operating cash flow of $9.29 billion covers payouts, but cigarette volumes fell 10% in 2025, and NJOY incurred $2.2 billion in impairments. Analysts grade the dividend a B due to cash flow timing issues and balance sheet concerns.

A Virginia federal judge dismissed Altria's lawsuit challenging the constitutionality of U.S. International Trade Commission (ITC) patent proceedings, refusing to halt an ITC vape patent case involving the company. According to the ruling, the ITC's processes are valid, impacting Altria's legal strategy in patent disputes.

Altria Group (MO) subsidiaries Helix Innovations and NJOY sued the FDA over its 2021 PMTA rule, arguing it violates the Tobacco Control Act's 180-day review deadline. The lawsuit claims FDA delays begin with Acceptance and Filing Reviews. FDA has reduced its backlog but Altria seeks a court order to vacate the rule. MO stock traded between $54.70 and $77.06 over the past year, closing at $69.56 on Wednesday.

Altria Group (NYSE: MO) sued the FDA over delays in tobacco product approvals, arguing they hinder innovation. The company offers a 6.09% dividend yield, but its stock is seen as 21.2% overvalued. Altria has a GF Score of 74, indicating strong profitability but average growth and financial strength. Insiders sold $2.4M in shares, while gurus show mixed activity. The lawsuit may impact Altria's product pipeline and market strategy.

Altria (MO) sued the FDA, seeking to force a review process overhaul for nicotine products. The company claims the FDA's current system delays approvals, allowing foreign competitors to gain market share. Altria argues the FDA violates a legal 180-day decision deadline. The FDA has not yet responded. MO is the ticker symbol for Altria.

Trivariate Research identified stocks with projected gross margin declines, including Apple (1.4%), Oracle (6%), and Altria Group (14%). Margin contractions have historically led to underperformance. Apple's CEO Tim Cook is stepping down, and its shares are up 16% in 2026. Oracle is down 23% YTD but analysts expect a 70% rebound. Altria Group's stock has risen 20% this year, with analysts forecasting minimal gains ahead.

Coca-Cola (KO) is up 30% YTD with guided EPS growth of 9-10%, while Altria (MO) yields over 6%. The Consumer Staples Select Sector SPDR Fund (XLP) has gained 11.39% YTD but has a blended yield near 2.5%. Owning KO, Procter & Gamble (PG), and MO directly offers a higher yield and no expense ratio, though Altria carries regulatory risks.

Altria Group (MO) raised its quarterly dividend by 4.7% to $1.11 per share and appointed Steven W. Presley as a new director. The dividend increase signals confidence in cash flow and shareholder returns, while Presley's appointment aims to strengthen leadership. Analysts project $20.9B revenue and $9.7B earnings by 2029, though regulatory risks in e-vapor products remain a concern.

Altria (MO) raised its quarterly dividend by 4.7% to $1.11/share, yielding ~6.4% at $68.37. The company has a strong free cash flow history but faces revenue decline and high debt. It guided for mid-single-digit dividend growth through 2028 and has a new contract manufacturing deal with Philip Morris International.